BPC-157’s Gastric Origins
BPC-157 was isolated from human gastric juice — a protein found in the stomach lining with apparent protective properties. This origin explains why gastrointestinal research is one of the most developed areas of BPC-157 study. The compound appears to be naturally cytoprotective in the GI environment.
Key GI Research Findings
Animal studies have observed BPC-157 accelerating healing of gastric ulcers, protecting the gastric mucosa from NSAID-induced damage, and improving healing of intestinal anastomoses (surgical reconnections of the intestine after resection). Inflammatory bowel disease models have shown reduced inflammation scores with BPC-157 treatment.
Oral Administration for GI Applications
Unlike most systemic applications where injectable BPC-157 is preferred, GI applications may be appropriate for oral administration. The compound appears to have local effects within the GI tract that do not require systemic absorption. Oral BPC-157 formulations are available through licensed compounding pharmacies.
The Research Limitation
The GI research base for BPC-157 is exclusively preclinical. No controlled human trials have been published. The animal data is compelling enough that physicians with functional medicine backgrounds use it for appropriate patients, but human efficacy and optimal dosing remain unknown.